WOW, I didn't realize this. I just checked Allergan's 10-Q first Q. It turns out that RESTASIS is a VERY important drug for Allergan! It is the companies no# 2 drug in sales. Their BOTOX (anti wrinke, sound familiar?)....is running 2011 at $364 million oper quarter. RESTASIS is running $162 million. And RESTASIS is growing 20% year over year. That should put RESTASIS sales at about $670 million for 2011. That is pushing Restasis towards the <<<BLOCKBUSTER>>> category....a huge money maker for AGN!
All that is going to dissappear in LESS than three years for Allergan....cuz I showd that the RESTASIS patent expires.
Since RESTASIS is the ONLY dry Eye drug approved, and AGN is all set up to sell and market dry eye drugs.....and I checked that AGN has no dry eye drug of in house research.....WHAT should Allergan do? Look for a NEW dry eye drug!
Sound familiar? Who may have one???
If RESTASIS is reaaching towards $700 million in sales, it IS almost a blockbuster drug, with hardly any patent life left. If RGRX can should a good pahse 2 of better efficacy that RESTASIS.....and is safe..then it is possible that TB 4 could be a near blockbuster drug too. More than ONE phara would be interested.
But it al rides on if the Phs 2 can show the efficacy needed..and what the USPO decides. An issued patent is critical to get the interest of AGN.
One would think more investors would take a shot/gamble/flyer on RGRX. An $18 million market cap? for an almost blockbuster drug category in dry eye...with only ONE drug approved and patent expiring?????